Korean medical artificial intelligence (AI) company, Kai Health, announced that its new embryo analysis software, Vita Embryo, has been granted a class three medical device licence as an innovative medical device.
The Ministry of Food and Drug Safety grants such licences to devices which have significantly improved, or are expected to significantly improve, safety and efficiency compared with existing methods. Vita Embryo is the first AI embryo analysis software to be awarded this licence in Korea.
Read more in the Korean Biomedical Review.